Modulation of C-reactive protein expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsRosanne M. Crooke, Mark J. Graham
Life of this patent
Estimating the term…
Abstract
Compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise oligonucleotides, targeted to nucleic acid encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for diagnosis and treatment of disease associated with expression of C-reactive protein are provided.
Claims42
An antisense compound 15 to 30 nucleobases in length targeted to a nucleic acid molecule encoding C-reactive protein, wherein said compound comprises a 15 nucleobase portion having at least 90% complementarity to at least a 15 nucleobase portion of nucleotides 1719 to 1738 of SEQ ID NO. 4.
An antisense compound 20 nucleobases in length targeted to a nucleic acid molecule encoding C-reactive protein, comprising:
- at least 16 consecutive nucleotides of SEQ ID NO:
- 205;
- a 5′ terminus having two to four 2′-O-methoxyethyl nucleotides;
- a 3′ terminus having two to four 2′-O-methoxyethyl nucleotides;
- and
- a 2′-deoxynucleotide portion twelve to sixteen nucleotides in length disposed between said 5′ terminus and said 3′ terminus.
An antisense oligonucleotide consisting the nucleobase sequence of SEQ ID NO:
- 205, having a 2′-deoxynucleotide portion fourteen nucleotides in length positioned between a 5′ terminus and a 3′ terminus, wherein said 5′ terminus has three 2′-O-methoxyethylnucleotides, wherein said 3′terminus has three 2′-O-methoxyethylnucleotides, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage, and wherein each cytosine is a 5-methylcytosine.
Dependencies are inferred from the claim text.